Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3073 |
Name | brain glioblastoma multiforme |
Definition | A brain glioma that has_material_basis_in abnormally proliferating cells derives_from glial cells, has_symptom seizure, headaches, nausea and vomiting, memory loss, changes to personality, mood or concentration; and localized neurological problems. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer brain glioma brain glioblastoma multiforme |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CDKN2A loss | Milciclib | brain glioblastoma multiforme | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | brain glioblastoma multiforme | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01112527 | Phase II | Dacomitinib | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | Completed | USA | 0 |
NCT01837862 | Phase Ib/II | Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole | A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas | Completed | USA | 0 |
NCT01891747 | Phase I | Bevacizumab + Temozolomide | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | Completed | USA | 0 |
NCT01954576 | Phase II | NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | Terminated | USA | 0 | |
NCT02052648 | Phase Ib/II | Temozolomide Indoximod | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |
NCT03522298 | Phase II | GDC-0084 | Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme | Completed | USA | 0 |